中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

70 records (took 0.017 seconds)

    METHOD FOR CONTROLLING THE FORMATION OF METALLIC NANOPARTICLES IN GLASS AND PRODUCTS THEREOF
    22.
    发明申请
    METHOD FOR CONTROLLING THE FORMATION OF METALLIC NANOPARTICLES IN GLASS AND PRODUCTS THEREOF 审中-公开

    公开(公告)号：US20200331791A1

    公开(公告)日：2020-10-22

    申请号：US16755628

    申请日：2018-10-12

    Applicant: THE UNIVERSITY OF ADELAIDE

    Inventor： Yunle WEI ,  Heike EBENDORFF-HEIDEPRIEM ,  Jiangbo ZHAO

    IPC: C03B19/09 ,  C03C14/00

    Abstract: A method of forming metallic nanoparticles in glass is disclosed that creates evenly distributed metallic nanoparticles with desired size in any glass type.Formation of a source of electrons trapped on the surface of the glass particles by crushing and grinding glass material into powder followed by heat treatment of the glass powder to neutralise metal ions doped in the glass by the trapped source of electrons, followed by the aggregation and growth of the metal into nanoparticles. The present method allows the homogeneous distribution of metal nanoparticles throughout the glass volume. The size and concentration of the metallic nanoparticles is controlled by the heat treatment temperature and duration as well as the amount of metal ions.

    System and method for generating an optical frequency standard
    23.
    发明授权
    System and method for generating an optical frequency standard 有权

    公开(公告)号：US10353270B2

    公开(公告)日：2019-07-16

    申请号：US15741481

    申请日：2016-07-01

    Applicant: THE UNIVERSITY OF ADELAIDE

    Inventor： Christopher Perrella ,  Philip Stephen Light ,  Andre Nicholas Luiten

    IPC: G02F1/37 ,  H01S3/067 ,  H01S3/13 ,  H01S3/00 ,  G02F1/35 ,  H01S3/23

    Abstract: A system for generating an optical frequency standard is described. The system is based on a two-color approach and includes a first laser source that generates a first laser output at a first frequency and a second laser source that generates a second laser output at a second frequency corresponding. The first and second laser outputs are then respectively input into first and second harmonic generators to form frequency-doubled first and second laser outputs. The system also includes a two-color stabilization arrangement to stabilize the sum of the frequencies generated by first and second laser sources, including, for example, an interaction region incorporating a laser active material. The interaction region can be a gas reference cell and the laser active material can be Rubidium (in vapor form) having a two-photon transition.

    COMBINATION TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN PATIENTS WITH RAS PATHWAY MUTATIONS
    28.
    发明申请
    COMBINATION TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA IN PATIENTS WITH RAS PATHWAY MUTATIONS 有权

    公开(公告)号：US20250154243A1

    公开(公告)日：2025-05-15

    申请号：US18889359

    申请日：2024-09-18

    Applicant: TARAN THERAPEUTICS, INC. ,  THE UNIVERSITY OF ADELAIDE

    Inventor： Cameron DURRANT ,  Daniel THOMAS

    IPC: C07K16/24 ,  A61K31/17 ,  A61K31/706 ,  A61K31/7068 ,  A61K39/00 ,  A61K45/06 ,  A61P35/02 ,  C12Q1/6886

    Abstract: Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from 10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from 10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a second therapeutic agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells, an increased percentage of CD116 and CD131 in CD34+ stem and progenitor cells in the subject compared to a healthy subject and/or an increased percentage of CD14+ cells in the subject compared to a healthy subject. A therapeutically effective amount of a hypomethylating agent or hydroxyurea may be further administered according to the provided methods.

    METHODS AND PRODUCTS FOR IMPROVING SPERM QUALITY
    29.
    发明申请
    METHODS AND PRODUCTS FOR IMPROVING SPERM QUALITY 有权

    公开(公告)号：US20250073221A1

    公开(公告)日：2025-03-06

    申请号：US18949880

    申请日：2024-11-15

    Applicant: THE UNIVERSITY OF ADELAIDE

    Inventor： Rebecca Louise Robker ,  Macarena Bermudez Gonzalez

    IPC: A61K31/4545 ,  A01N1/02 ,  C12N5/076

    Abstract: Disclosed are methods and products for improving the quality of sperm, methods for treating subjects to improve sperm quality or improve fertility, and use of sperm with improved quality in assisted reproductive technologies, including exposing the sperm to BGP-15 and/or a derivative thereof, such as BGP-15, propanolol, bimoclomol, arimoclomal, NG94, iroxanadine, and/or a pharmaceutically acceptable derivative, prodrug, solvate, salt, tautomer, stereoisomer, and/or racemate thereof.

Patent Agency Ranking